Fayosim (levonorgestrel and ethinyl estradiol) tablets USP, (0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0...

FDA Drug Recall #D-1057-2019 — Class II — March 22, 2019

Recall Summary

Recall Number D-1057-2019
Classification Class II — Moderate risk
Date Initiated March 22, 2019
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Lupin Pharmaceuticals Inc.
Location Baltimore, MD
Product Type Drugs
Quantity 12,464 cartons

Product Description

Fayosim (levonorgestrel and ethinyl estradiol) tablets USP, (0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg) and ethinyl estradiol tablets USP, (0.01 mg), packaged in 1 Extended-Cycle Wallet of 91 Tablets packed in a pouch(NDC 68180-860-11); one pouch per carton (NDC 68180-860-12), Rx only, Distributed by: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Pithampur (M.P.) - 454775, INDIA.

Reason for Recall

Failed Impurities/Degradation Specifications: Out-of-specification results observed in related substance test (Any Other Individual Impurity and Total impurities) in Ethinyl Estradiol Tablets USP 0.01mg at 12 month long term stability study.

Distribution Pattern

Nationwide in the USA.

Lot / Code Information

Lot #: L800016, Exp 12/2019; L800721, Exp 05/2020

Other Recalls from Lupin Pharmaceuticals Inc.

Recall # Classification Product Date
D-0541-2026 Class II Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx... Apr 24, 2026
D-0220-2026 Class II Ganirelix Acetate Injection, 250 mcg/0.5mL, Sin... Nov 13, 2025
D-0227-2026 Class II Sertraline Hydrochloride Tablets USP, 100 mg, 9... Nov 5, 2025
D-0542-2025 Class II Amlodipine and Benazepril HCl Capsules USP 2.5 ... Jul 2, 2025
D-0537-2025 Class II clomiPRAMINE Hydrochloride Capsules USP 25 mg, ... Jun 27, 2025

Frequently Asked Questions

Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.